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Cystic Fibrosis (CF) is a recessive genetic disorder caused by mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR). CFTR mutations cause
dysregulation of channel function with intracellular accumulation of misfolded proteins
and endoplasmic reticulum (ER) stress, with activation of the IRE1α-XBP1 pathway
that regulates a subset of unfolded protein response (UPR) genes. This pathway
regulates a group of genes that control proinflammatory and metabolic responses in
different immune cells; however, the metabolic state of immune cells and the role of
this pathway in CF remain elusive. Our results indicate that only innate immune cells
from CF patients present increased levels of ER stress, mainly affecting neutrophils,
monocytes, and macrophages. An overactive IRE1α-XBP1 pathway reprograms CF
M1 macrophages toward an increased metabolic state, with increased glycolytic rates
and mitochondrial function, associated with exaggerated production of TNF and IL-6.
This hyper-metabolic state, seen in CF macrophages, is reversed by inhibiting the
RNase domain of IRE1α, thereby decreasing the increased glycolic rates, mitochondrial
function and inflammation. Altogether, our results indicate that innate immune cells from
CF patients are primarily affected by ER stress. Moreover, the IRE1α-XBP1 pathway
of the UPR is responsible for the hyper-metabolic state seen in CF macrophages,
which is associated with the exaggerated inflammatory response. Modulating ER stress,
metabolism and inflammation, by targeting IRE1α, may improve the metabolic fitness of
macrophages, and other immune cells in CF and other immune-related disorders.
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INTRODUCTION
CF is one the most common life limiting autosomal recessive
genetic disorder, mainly affecting the lungs and digestive system.
CF is caused by mutations in the CFTR gene, which regulates
ion transport in epithelial, and immune cells. CFTR mutations
result in abnormal ion channel function and intracellular
accumulation of misfolded proteins leading to ER stress and
activation of the IRE1α-XBP1 pathway of the UPR (1). Activation
of IRE1α leads to splicing of XBP1 (XBP1s), the latter being
a transcription factor involved in the regulation of several
cellular pathways, including inflammation, and metabolism (2–
4). Inflammation is one of the most common complications of
CF, mainly caused by recurrent opportunistic infections, themost
common being Pseudomonas aeruginosa, Staphylococcus aureus,
and Haemophilus influenza, leading to the production of several
proinflammatory cytokines, such as IL-8, IL-6, IL-1β, IL-18, and
TNF (5).
In previous studies, it has been suggested that loss of CFTR
function in monocytes and macrophages contributes to the
exaggerated inflammatory responses observed in patients with
CF (6, 7). Alveolar macrophages are in part responsible for
these exaggerated inflammatory responses, partly due to the
upregulation of XBP1s inducing high levels of IL-6 production
(8). Other studies have reported an increased TLR-4 expression
in monocytes from patients with CF, which may also contribute
to the hyper-inflammatory state (9, 10). Macrophages are divided
broadly into two classes, resident macrophages, and monocyte-
derived macrophages, and the latter can be polarized into a
proinflammatory (M1) classically activated, or anti-inflammatory
(M2) alternatively activated phenotype (11). The degree of
M1/M2 macrophage polarization has been reported to be
altered in patients with CF, with potential implications for
their condition (12, 13). The IRE1α-XBP1 pathway is crucial
for M1/M2 macrophage polarization, favoring M1 macrophage
polarization while supressing M2 macrophage polarization when
overactive (14). Recently, an important role of the IRE1α-
XBP1 pathway was described in regulating the metabolic fitness
of immune cells (4); however, the metabolic state and the
implications of the IRE1α-XBP1 pathway in the pathogenesis of
CF have not been fully elucidated. Since atypical activation of the
UPR has been reported in CF (15), characterized by high levels
of XBP1s and IL-6, we aimed to investigate firstly, whether these
UPR abnormalities were present in individual subsets of immune
cells, then secondly, the nature of the metabolic conditions of
immune cells affected by ER stress and finally, the implications
of the IRE1α-XBP1 pathway in the metabolic profile of CF
immune cells.
We found that ER stress is present in CF innate immune cells,
affecting human bronchial epithelial cells (HBECs), neutrophils,
monocytes and M1 macrophages, and is completely absent in
the lymphoid cells we studied. We also report a macrophage
polarization imbalance, with suppression of M2 macrophage
polarization in patients with CF. Even though there were no
differences in the proportion of M1 macrophages we found
high levels of IL-6 and TNF, with an associated activation of
the IRE1α-XBP1 pathway. Previously unreported, we found that
TABLE 1 | Patient demographics and clinical data.
CF (n = 62) HC (n = 37)
Age range (years) 19–50 (32) 21–44 (29)
Male (%) 54.84% 48.65%
CFTR GENOTYPE
DF508/DF508 88.71% N/A
DF508/621+1 (G>T) 1.61% N/A
DF508/G551D 1.61% N/A
W1282X/W1282X 1.61% N/A
DF508del/c.1521_1523delCTT 4.84% N/A
3484C>T (p.Arg1162X)/R1162X 1.61% N/A
BMI (mean) 23.1 N/A
FEV1 (%) 45.9% N/A
the metabolic profile of CF monocytes and M1 macrophages
was significantly different to those of healthy controls and these
differences could be attributed to activation of the IRE1α-XBP1
pathway. M1 macrophages from CF patients showed elevated
glycolic rates and mitochondrial function with an increased
glycolytic capacity, glycolytic reserve, mitochondrial respiration,
and ATP production. Finally, we showed that the increased
metabolic and inflammatory profiles of CF M1 macrophages is
primarily due to overactivation of the IRE1α-XBP1 pathway,
which could be reversed by inhibition of the RNase domain
of IRE1α.
MATERIALS AND METHODS
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents
should be directed to and will be fulfilled by the Lead Contact,
Michael F. McDermott (m.mcdermott@leeds.ac.uk).
Human Subjects
All work involving human samples from patients with CF or
HC volunteers was approved by the Health Research Authority,
Research Ethics Committees reference 17/YH/0084. Patients
with CF were recruited from the Adult Cystic Fibrosis Unit
at St. James’s University Hospital, Leeds, UK. All patients were
diagnosed with CF and had two disease-causing CFTRmutations
and clinical features consistent with the diagnosis of CF (Table 1).
Patients who were post lung transplant or on CFTR modulators
were excluded from the study. Informed written consent was
obtained from all participants at the time of the sample collection.
Age and sex matched healthy controls were recruited from the St.
James’s University Hospital, Leeds, UK.
Cell Lines
The well-characterized human bronchial epithelial cell
lines, BEAS2-B (WT), CuFi-1(1F508/1F508), CuFi-4
(G551D/1F508) were obtained from ATCC, all the details
regarding these cell lines are deposited in their web page (see
table of reagents). All cells were grown on Cell+ surface plates or
flasks (Sarstedt). BEAS-2B were cultured in LHC basal medium
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(ThermoFisher Scientific) supplemented with 10% FBS, 50
U/ml penicillin and 50µg/ml streptomycin). CuFi-1 and CuFi-4
were cultured in LHC-9 medium (ThermoFisher Scientific), as
described by the manufacturer.
Cell Line Work
Cell lines were seeded at 1 × 106 cells/ml in 6 well plates
and cultured in the appropriate growth media. When referred
cells were stimulated with LPS (100 ng/ml) and Thapsigargin
(Tg) (300 nM) for 4 h. The IRE1α inhibitor, 4 µ8c (50µM),
was used 30min before stimulation, whenever mentioned. For
the detection of IRE1α and pIRE1α, cells were detached,
washed, pelleted, fixed, and permeabilized for 20min, using the
Fixation/Permeabilization Kit listed in the table of reagents.
Cells were washed twice and stained with IRE1α (Santa Cruz)
and pIRE1α (GeneTex) antibodies, or their respective isotype
controls, for 30min. After a final wash the cells were resuspended
in brilliant stain buffer (BSB) in FACS collection tubes.
Human Blood and Isolation of Immune
Cells
All blood samples were collected in EDTA pre-coated tubes and
processed the same day of collection. PBMCs were isolated from
whole blood using a standard density gradient centrifugation
method. Blood was mixed with an equal volume of DPBS
without Ca2+ and Mg2+ containing 2% heat inactivated fetal
bovine serum (FBS), carefully layered onto of Lymphoprep (Axis-
Shield) and centrifuged at 1159xg for 20min without brakes.
The white buffy layer was carefully removed and washed twice
in DPBS (2% FBS) by centrifuging at 180xg for 10min without
brakes, to remove platelets. Finally, PBMCs were resuspended
in complete RPMI medium (Merck) containing 10% FBS, 50
U/ml penicillin, 50µg/ml streptomycin and 1% L-Glutamine. 2
× 106 PBMCs from patients with CF or HC volunteers were
plated in 6 well plates and stimulated the day after for 4 h
with LPS (10 ng/ml). Lymphocytes were isolated from blood
using the EasySep Direct Human Total Lymphocyte Isolation
Kit (StemCell), plated 2 × 106 cell/ml, and stimulated the day
after for 4 h with LPS (10 ng/ml). Neutrophils were isolated from
blood using the EasySep Direct Human Neutrophil Isolation Kit
(StemCell), plated 3 × 106 cell/ml, and stimulated the same day
for 4 h with LPS (10 ng/ml). Monocytes were isolated the same
day the PBMCs were obtained using the Pan Monocyte Isolation
Kit, human (Miltenyi Biotec), following all the manufacturer
instructions, plated 1 × 106 cell/ml and stimulated the day after
for 4 h with LPS (10 ng/ml). All cells were cultured in complete
RPMI medium (Merck) and kept in a humidified incubator at
37◦C, 5% CO2.
M1/M2 Macrophage Polarization
Negatively selectedmonocytes, as described before, were cultured
in complete RPMI medium (Merck) supplemented with either
20 ng/mL human GM-CSF (PeproTech), for M1 differentiation,
or 20 ng/mL human M-CSF (PeproTech), for M2 differentiation,
and incubated for 6 days adding fresh media with the respective
factors on day 3. On day 6 M0 macrophages were activated with
100 ng/mL human IFN-γ (PeproTech) and 50 ng/mL LPS, forM1
macrophage polarization, or 20 ng/mL IL-13 (PeproTech) and
20 ng/mL IL-4 (PeproTech), for M2 macrophage polarization,
and incubated for 24 h. M1 macrophages were stimulated with
100 ng/ml LPS for 4 h (Figure 3A). For M1/M2 macrophage
characterization using flow cytometry, monocytes seeded at a
density of 1× 106 cell/ml were cultured in tissue culture-treated 6
well plates, stimulated and activated with their respective factors.
On day 7 cells were washed twice with DBPS without Ca2+ and
Mg2+, and detached using DPBS with EDTA 10mM. Cells were
washed twice with DPBS (2% FBS), pelleted and resuspended
in BSB with human and mouse serum for 30min on ice. Cells
were washed, pelleted, and stained with the surface markers for
M1 (CD14+, HLA-DR+, CD274+ and CD86+) and M2-type
(CD14+, HLA-DR-, and CD206+) for 30min on ice. Then, cells
were washed, pelleted, fixed, and permeabilized for 20min on ice.
The intracellular markers IL-10 and TNFwere then added to fully
characterize the M1/M2 macrophages. After a final wash cells
were resuspended in BSB in FACS collection tubes. All antibodies
used are listed in detail in the table of regents. All the gating
strategies are shown in Supplementary Figure 2.
RNA Analysis
Total RNA isolation was performed using TRIzol reagent and
the Phasemaker Tubes (ThermoFisher Scientific) according
to the manufacturer’s protocol. RNA quality and quantity
were further determined by 260/280 and 260/230 ratios
using a NanoDrop spectrophotometer. RNA was converted
to cDNA using no more than 1mg of sample with the
High-Capacity cDNA Reverse Transcription Kit (ThermoFisher
Scientific). XBP1 mRNA splicing was detected by reverse
transcription (RT)-PCR using the following set of primers:
Forward 5′-CTGAAGAGGAGGCGGAAGC-3′ and reverse 5′-
AATACCGCCAGAATCCATGG-3′, which recognize both the
XBP1s and XBP1u mRNA. The transcripts were then identified
on a 3% agarose gel. Real-time quantitative PCR was done using
PowerUp SYBR Green Master Mix reagent or TaqMan universal
PCR Master Mix in the QuantStudio 7 Flex Real-Time PCR
System (ThermoFisher Scientific) to determine the mRNA levels
of the reported genes. mRNA levels were normalized to the
levels of HPRT and PPIA RNA transcripts for the cell lines
and HPRT for lymphocytes, neutrophils, monocytes and M1
macrophages. All the primers used for qPCR are listed in the
Supplementary Table 1. All primers were optimized for specific
amplification of the target gene.
Cytokine Detection
Cytokines levels from cell cultured media were detected by
the IL-6, TNF, and IL-10 ELISAs kits listed in the table
of reagents, following the manufactures recommendations. In
general, ELISA plates were coated with 100 µl cytokine capture
antibody in PBS overnight at 4◦C. Plates were washed 3
times with PBST (PBS containing 0.5% Tween 20) and the
wells blocked in 300 µl assay buffer (0.5% BSA, 0.1% Tween
20 in PBS) by incubating for 1 h. Then, plates were washed
twice with PBST and 100 µl of sera/culture supernatants,
together with appropriate standards, were added to wells in
duplicates. 50 µl of detection antibody was added to all
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wells, and incubated for 2 h. After incubation, the plates were
washed 5 times with PBST and 100 µl of tetramethybenzidine
(TMB) substrate solution (Sigma) were added to all wells
and incubated for 30min. The reaction was stopped by
adding 100 µl of 1.8N H2SO4 and absorbance measured
at 450 nm and reference at 620 nm. All incubation steps
were done at room temperature with continual shaking at
700 rpm.
Flow Cytometry
The CytoFLEX-S was used for the detection of (PE)
IRE1α and (PerCP) pIRE1α in the cell lines. For the
characterization of M1/M2 macrophages the surface and
intracellular markers, referenced in the M1/M2 macrophage
polarization section, were used and analyzed in the BD
Bioscience FACS Calibur. Compensation was done by
fluorescence minus one (FMO) for all the antibodies. The
pIRE1α (GeneTex) and its Rabbit IgG isotype control
(GeneTex) antibodies were conjugated using the LYNX
Rapid PerCP Antibody Conjugation Kit, as per the
manufacture’s recommendations.
Protein Detection of XBP1s
For the detection of XBP1s and HPRT protein, samples were
prepared in RIPA lysis buffer (10mM Tris-Cl, 1mM EDTA,
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS and
140mM NaCl) with phosphatase and protease inhibitors listed
in the table of reagents and heated at 95◦C for 5min. Protein
concentration was determined using the Pierce BCA Protein
Assay Kit. Equal protein concentration was loaded and resolved
by 10% SDS-PAGE on Tris-glycine gels and then transferred
to Hybond PVDF membranes. Following electrotransfer in
transfer buffer (25mM Tris, 192mM glycine, pH 8.3, 20%
methanol) at 100V for 1 h, the membranes were blocked
for 1 h in blocking solution (PBS containing 0.1% Tween 20
and 5% (w/v) non-fat milk). After 3 washes in PBST (PBS
with 0.5% Tween 20), primary antibodies were incubated
with PVDF membrane overnight at 4◦C. The membrane was
washed 3 times with PBST and secondary antibody HRP-
linked antibody was added and incubated for 1 h with constant
rocking at room temperature. The membrane was washed 5x
with PBST and 3ml of ECL detection system (Merck) were
added to the membrane for 1min, before being imaged with
the ChemiDoc Imaging system (Bio-Rad). Primary antibodies
used, purified anti-XBP-1s Antibody (BioLegend) at 1/250
dilution, HPRT Antibody (Santa Cruz) at 1/500 dilution.
Secondary antibody used, Goat anti-Rabbit IgG (H+L) Poly-
HRP Secondary Antibody (ThermoFisher Scientific), was diluted
at 1/5000 in PBST.
Metabolic Experiments for ECAR and OCR
Negatively isolated monocytes, as previously described, were
seeded at a density of 1.0 × 105 in XF96 cell-culture microplates
previously coated with CellTak (Corning), according to the
manufacturer’s instructions, and wait 1 h for cellular adherence.
Immediately after, ECAR and OCR measurements were
analyzed on an XFe96 Extracellular Flux Analyzer (Agilent).
For the experiments involving M1 macrophages, initially
cells were grown as described in the M1/M2 macrophage
polarization section; on day 6, cells were detached using
Accutase (ThermoFisher Scientific) and seeded at a density of 3.0
× 104 in XF96 cell-culture microplates. The inhibitory effects of 4
µ8c 50µM (Merck) and MKC-3,946 10µM (Cayman Chemical)
were examined by pre-treating macrophages 30min before the
addition of LPS and IFNγ, then the cells were cultured for a
further 24 h in complete RMPI medium for full activation. After
activation, the supernatants were collected for cytokine detection,
cells were washed twice and media was changed for Agilent
seahorse XF base medium containing 10mM Glucose (only for
the Mito Stress Kit), 2mM L-glutamine, 1mM sodium pyruvate,
and 1mM HPES. ECAR and OCR measurements were analyzed
on an XFe96 Extracellular Flux Analyzer (Agilent). Once basal
ECAR and OCR measurements were obtained, ECAR changes
were recorded in response to glucose (10mM), oligomycin
(1µM), 2-Deoxy-D-glucose (2-DG, 50mM) following the
instructions stated in the XF Cell Glycolysis Stress Test Kit
(Agilent); or stimulated with oligomycin (1µM), FCCP (1µM),
and rotenone/antimycin A (0.5µM) following the instructions
stated in the XF Cell Mito Stress Test Kit (Agilent). All the
metabolic parameters were calculated as follow. For the XF Cell
Glycolysis Stress test: glycolysis = (maximum rate measurement
after glucose stimulation)–(rate measurement before glucose
stimulation); glycolytic capacity= (maximum rate measurement
after glucose stimulation)–(maximum rate measurement after
oligomycin stimulation); glycolytic reserve = (maximum rate
measurement after oligomycin stimulation)–(rate measurement
before oligomycin stimulation). For the XF Cell Mito Stress
test: basal respiration = (measurement before oligomycin
stimulation)–(rate measurement after rotenone/antimycin A
stimulation); proton leak = (minimum rate measurement
after oligomycin stimulation)–(minimum measurement after
rotenone/antimycin A stimulation); maximal respiration
= (maximum rate measurement after FCCP stimulation)–
(minimum rate measurement after rotenone/antimycin
A stimulation); reserve respiratory capacity = (maximal
respiration)–(basal respiration); ATP production = (basal
respiration)–(minimum rate measurement after oligomycin
stimulation). Normally 3–5 technical replicates per sample
were examined. Immediately after the metabolic analysis,
cells were fixed for 10min in methanol/acetone (4:1) and cell
number of each well was determined by nuclear DNA staining
with DAPI (BD Biosciences), ECAR and OCR values were
normalized accordingly.
Quantification and Statistical Analysis
All statistical details of experiments are described in each
of the figure legends. GraphPad Prism 7 software was used
to do all analyses. Data are presented as mean ± SEM.
Statistical significance determined using the Bonferroni-Dunn
correction method for unpaired independent student’s t-test. P-
values of <0.05 were considered to be statistically significant.
Nonparametric tests were used to compare the medians
between groups.
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Table of Reagents
Reagents Source Identifier
ANTIBODIES
IRE1 alpha (phospho Ser724) GeneTex Cat# GTX63722; RRID: N/A
Rabbit IgG isotype control GeneTex Cat# GTX35035; RRID: N/A
IRE1α Antibody (B-12) PE Santa Cruz Cat# sc-390960-PE; RRID: N/A
Normal mouse IgG1 PE (Isotype) Santa Cruz Cat# sc-2866; RRID: AB_737219
V500 Mouse Anti-Human CD14 BD Biosciences Cat# 561391; RRID: AB_10611856
Anti-HLA-DR PerCP BD Biosciences Cat# 347402; RRID: N/A
FITC Mouse Anti-Human CD206 BD Biosciences Cat# 551135; RRID: AB_394065
PE Rat Anti-Human IL-10 BD Biosciences Cat#; RRID: AB_397227
APC Mouse Anti-Human CD274 BD Biosciences Cat# 563741; RRID: AB_2738399
PE-Cy7 Mouse Anti-Human CD86 BD Biosciences Cat# 561128; RRID: AB_10563077
BV421 Mouse Anti-Human TNF BD Biosciences Cat# 562783; RRID: AB_2737790
Purified anti-XBP-1s Antibody BioLegend Cat# 619501; RRID: AB_315907
HPRT Antibody (FL-218) Santa Cruz Cat# sc-20975; RRID: N/A
Goat anti-Rabbit IgG (H+L) Poly-HRP Secondary Antibody ThermoFisher Scientific Cat# 32260; RRID: AB_1965959
BIOLOGICAL SAMPLES
Human Blood Samples St. James’s University Hospital Health Research Authority REC reference 17/YH/0084
Chemicals, Peptides, and Recombinant Proteins
Lymphoprep Axis Shield Cat# 1114544
EasySep Direct Human Total Lymphocyte Isolation Kit StemCell Cat# 19655
EasySep Direct Human Neutrophil Isolation Kit StemCell Cat# 19666
Pan Monocyte Isolation Kit, human Miltenyi Biotec Cat# 130-096-537
Recombinant Human GM-CSF PeproTech Cat# 300-03
Recombinant Human M-CSF PeproTech Cat# 300-25
Recombinant Human IFN-γ PeproTech Cat# 300-02
Recombinant Human IL-13 PeproTech Cat# 200-13
Recombinant Human IL-4 PeproTech Cat# 200-04
LPS InvivoGen Cat# tlrl-3pelps
4µ8c Merck Cat# 412512
MKC-3946 Cayman Chemical Cat# 19152
PowerUp SYBR Green Master Mix ThermoFisher Scientific Cat# A25780
TaqMan Universal PCR Master Mix ThermoFisher Scientific Cat# 4304437
TRIzol Reagent and Phasemaker Tubes Complete System ThermoFisher Scientific Cat# A33251
Thapsigargin Merck Cat# T9033
Tunicamycin Cell Signaling Technologies Cat# 12819S
PhosSTOP Merck Cat# 4906845001
Pierce Protease Inhibitor Mini Tablets ThermoFisher Scientific Cat# A32955
Immobilon Western Chemiluminescent HRP Substrate Merck Cat# WBKLS0500
COMMERCIAL ASSAYS
High-Capacity cDNA Reverse Transcription Kit ThermoFisher Scientific Cat# 4368814
ELISA IL-6 Human ThermoFisher Scientific Cat# CHC1263
ELISA TNF alpha Human ThermoFisher Scientific Cat# CHC1753
ELISA IL-10 Human ThermoFisher Scientific Cat# CHC1323
LYNX Rapid PerCP Antibody Conjugation Kit Bio-Rad Cat# LNK072PERCP
Glycolysis Stress Test Kit Agilent Technologies Cat# 103020-100
Pierce BCA Protein Assay Kit ThermoFisher Scientific Cat# 23225
CELL LINES
BEAS-2B cell line ATCC ATCC CRL-9609
CuFi-1 cell line ATCC ATCC CRL-4013
CuFi-4 cell line ATCC ATCC CRL-4015
SOFTWARE
GraphPad Prism7 Graphpad software N/A
CytExpert Software Beckman Coulter N/A
Flow Jo Vx0.7 FlowJo, LLC N/A
Agilent Seahorse Wave Agilent Technologies N/A
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RESULTS
ER Stress and UPR Activation in Different
Immune Cells
We primarily analyzed ER stress and UPR activation in Human
Bronchial Epithelial Cells (HBECs), as these cells are the first line
of defense in the lung and important players in the pathogenies
of CF. Three main UPR independent pathways have been
described, with the already mentioned IRE1α-XBP1 pathway, the
PERK arm responsible for the activation of ATF4, GADD34,
and CHOP, and the less well characterized ATF6 (16). We
found that CF HBECs harboring class II (1F508/1F508) and
class III (G551D/1F508) mutations showed an increase in ER
stress, mainly by upregulation of BiP, XBP1s, CHOP and IL-6
transcripts, as described before (Figure 1A) (15). Interestingly,
CF HBECs bearing two copies of the 1F508 mutation not only
showed upregulation of the transcripts aforementioned, but also
IRE1α, ATF6, PERK, XBP1u, ATF4, and GADD34 (Figure 1A).
We also found significantly higher levels of IRE1α, at the protein
level, and increased phosphorylation of IRE1α (pIRE1α) in
the CF HBECs compared to healthy HBECs (Figures 1B–D).
As previously mentioned, XBP1s activates the transcription of
proinflammatory cytokines, such as IL-6 and TNF. In line with
other publications, we confirmed that LPS-induced XBP1s drives
the production of IL-6, which can be abrogated by the IRE1α
inhibitor, 4 µ8c, in CF HBECs (Figures 1E–G) (8).
There is evidence of an atypical activation of the UPR in
Peripheral Blood Mononuclear Cells (PBMCs) from patients
with CF under basal conditions (15); however, there is no data
showing how PBMCs respond upon bacterial challenges or any
other type of ER stressor. Therefore, we analyzed ER stress
and UPR activation in PBMCs from patients with CF, at basal
conditions, after LPS challenge, and under ER stress conditions
induced by Tunicamycin (Tn) and Thapsigargin (Tg). At basal
conditions IRE1α and GADD34were significantly upregulated in
CF PBMCs, and IL-6 downregulated (Figure 2A); however, after
stimulation with LPS we detected significant upregulation in BiP,
IRE1α, XBP1s, ERdj4, ATF4, GADD34, TNF, and IL-6, compared
to healthy controls (HC) volunteers (Figure 2A). Furthermore,
we detected similar results after ER stress induction with Tn by a
significant upregulation of BiP and IRE1α, and after stimulation
with Tg with a significant higher expression in PERK and XBP1s
(Supplementary Figures 1A–H). We then investigated whether
these UPR abnormalities were still present in individual subsets
of immune cells, as PBMCs are a mixed population of lymphoid
and myeloid cells. No differences were detected in lymphoid cells
from patients with CF compared to HC (Figure 2B); however,
CF neutrophils and monocytes presented upregulation of several
ER stress markers (Figures 2C,D). CF neutrophils presented
higher levels of BiP, IRE1α, ATF4, and CHOP at basal conditions,
whereas only BiP and CHOP were significantly upregulated after
LPS stimulation (Figure 2C). CFmonocytes showed higher levels
of IRE1α and ATF4 at basal conditions, and IRE1α, PERK, ERdj4,
CHOP, GADD34, and TNF after LPS stimulation (Figure 2D).
These results indicate that ER stress and UPR activation is only
present in CF innate immune cells and, moreover, it can be
influenced by LPS stimulation. Furthermore, this UPR activation
is differentially activated in HBECs, neutrophils and monocytes,
with a consistent upregulation of IRE1α.
Polarization of M1/M2 Macrophages
Monocytes are the natural precursors of macrophages, when
these are recruited to site of inflammation, and these cells
were the most affected by ER stress. Two recent studies have
reported differences in M1/M2 macrophage polarization in
CF, with contradicting conclusions (12, 13), suggesting further
investigations are required to resolve this phenomenon. To
do this we used freshly isolated monocytes from CF patients
or HC volunteers and differentiate them into either a M1
(CD14+, CD274+, CD86+, HLA-DR+ and Hi TNF) or M2
(CD14+, CD206+, HLA-DR- and Hi IL-10) phenotype as
described in Figure 3A. After polarization, we observed a
significantly lower amount of M2 macrophages in patients
with CF with lower amounts of IL-10 (Figures 3B,C). While
the proportion of CF M1 macrophages was unaffected, the
amount of IL-6 produced by these proinflammatory cells was
significantly increased (Figures 3D,E). As seen in the HBECs,
and also in alveolar macrophages (AM) (8), the upregulation
of XBP1s is proportional to the exaggerated inflammatory
response seen with IL-6 (Figures 1E–G). We found that in
CF M1 macrophages XBP1s was significantly increased, and
correlated with the upregulation of TNF, IL-6, BiP, and ERdj4
(Figure 3F); furthermore these changes were still observed after
a second challenge of LPS, with the exception of ERdj4, and
the downregulation of PERK (Figure 3F).To further support
the finding that XBP1s is present in CF M1 macrophages, we
performed a conventional reverse transcription (RT)-PCR to
detect splicing of XBP1. We consistently detected XBP1s in the
majority of M1 macrophages from CF patients (Figure 3G).
We also detected a significantly higher production of XBP1s
at the protein level in CF M1 macrophages, while XBP1s
was not detected in M2 macrophages (Figures 3H–J). Taken
together, these results support a defect in CF M2 macrophage
polarization, demonstrating the existence of ER stress in CF M1
macrophages, with a potentially distinctive role of XBP1s driving
this exaggerated inflammatory response.
Metabolic Profile of Monocytes and M1
Macrophages
When macrophages are activated toward a M1 proinflammatory
phenotype, they increase the level of ATP production by
switching to glycolytic metabolism (17). Recent publications
have demonstrated that the IRE1α-XBP1 pathway regulates
M1/M2 macrophage polarization controlling mitochondrial
activity and energy consumption in immune cells (4, 14). It is
well accepted that patients with CF present an energy imbalance
with an increased energy consumption, which is compensated
with a hyper-caloric diet. We speculated that the IRE1α-XBP1
pathway was involved in this increased energy consumption,
seen in CF patients, with further repercussions in M1/M2
polarization, metabolism and inflammation. The glycolytic rate
and mitochondrial function of immune cells can be calculated
in real time by measuring the extracellular acidification rate
(ECAR) and the oxygen consumption rate (OCR), accordingly.
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FIGURE 1 | ER Stress and UPR activation in CF HBECs. (A) mRNA relative expression of ER stress and UPR markers BiP, IRE1α, ATF6, PERK, XBP1s, XBP1u, ATF4,
CHOP, GADD34, and IL-6 in BEAS-2B, CuFi-1, and CuFi-4 cell lines. (B–D) Single cells were gated and used to measure the mean fluorescent intensity of each cell
line though flow cytometry; IRE1α (B) and phosphorylated IRE1α (C) protein expression was measured with monoclonal conjugated antibodies (PE, PerCP) in
BEAS-2B, CuFi-1, and CuFi-4 cell lines (D). All antibodies were normalized with their respective isotype controls, in each cell line. (E–G) XBP1s and IL-6 were
measured in response to LPS (100 ng/ml) and Tg (300 nM) for 4 h measuring XBP1s mRNA (E), IL-6 mRNA (F) and IL-6 cytokine levels (G); when referred, the IRE1α
inhibitor, 4 µ8c (50µM), was used 30min before each stimulation. All data is presented as mean ± SEM and mRNA data represented by logarithmic scale base 10.
Statistical significance was determined using 2way-ANOVA, Dunnett’s test (A), unpaired (D) or paired (E–G) independent student’s t-test. *p < 0.05, **p < 0.01, ***p <
0.001. n = 4 biological replicates for all cell lines.
At basal conditions the glycolytic rate of monocytes, but not
mitochondrial function, was significantly increased in patients
with CF compared to HC volunteers (Figures 4A,B). As
expected, stimulation of monocytes with LPS increased their
glycolytic rate and mitochondrial function in both HC and
patients with CF, with larger changes in the glycolytic rate
and mitochondrial function in CF monocytes (Figures 4A,B).
We also observed an increase in the glycolytic capacity and
reserve of CF monocytes compared to HC monocytes, with
no significant change in glycolysis (Figures 4C,D). Next, we
measured the glycolytic rate and mitochondrial function of M1
macrophages, derived from isolated monocytes and cultured
as described previously (Figure 3A). We noticed that M1
macrophages from CF patients displayed a higher glycolytic
rate and mitochondrial function as compared to the HC
M1 macrophages (Figures 4E,F). Furthermore, these altered
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FIGURE 2 | ER stress and UPR activation in immune cells. mRNA relative expression of ER stress and UPR markers BiP, IRE1α, PERK, XBP1s, ERdj4, ATF4, CHOP,
GADD34, TNF, and IL-6. (A) Primary PBMCs from HC volunteers (n = 8) and patients with CF (n = 14) at basal conditions and stimulated with LPS (10 ng/ml) for 4 h.
(B) Isolated lymphocytes from HC volunteers (n = 6) and patients with CF (n = 6) at basal conditions and stimulated with LPS (10 ng/ml) for 4 h. (C) Freshly isolated
Neutrophils from HC volunteers (n = 6) and patients with CF (n = 6) at basal conditions and stimulated with LPS (10 ng/ml) for 4 h. (D) Isolated monocytes from HC
volunteers (n = 6) and patients with CF (n = 6) at basal conditions and stimulated with LPS (10 ng/ml) for 4 h. The 14 CF patients and 8 HC volunteers in (A) are
independent from the other panels. The 6 CF patients and 6 HC volunteers in (B–D), are the same. All data are represented by logarithmic scale base 10 and
presented as mean ± SEM. All n values represent biological independent samples. Statistical comparisons were performed by unpaired independent student’s t-test,
*p < 0.05, **p < 0.01, ***p < 0.001; ND, Not detected.
metabolic changes were detected before and after activation of
M1 macrophages (Figures 4E,F). Finally, the glycolytic capacity
and reserve of CF M1 macrophages were also elevated as seen
in the CF monocytes (Figures 4G,H). Following on from these
findings we analyzed the expression of some key metabolic
enzymes, hexokinase 2 (HK2), pyruvate dehydrogenase
kinase 4 (PDK4), 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase (PFKFB1), estrogen related receptor alpha 1
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FIGURE 3 | Continued
Frontiers in Immunology | www.frontiersin.org 9 August 2019 | Volume 10 | Article 1789
Lara-Reyna et al. Metabolic Reprogramming of CF Macrophages
FIGURE 3 | Polarization of M1/M2 Macrophages and XBP1s expression. (A) Monocytes were differentiated into macrophages for 6 days with GM-CSF 20 ng/ml or
M-CSF 20 ng/ml, then M1-type macrophage activation was achieved by supplementing growth media with 100 ng/ml human IFNγ, and 50 ng/ml LPS. M2-type
macrophage activation was achieved by supplementing growth media with 20 ng/ml IL-13 and 20 ng/ml IL-4. Macrophages were characterized as M1-type (markers-
CD14+, HLA-DR+, CD274+, CD86+ TNFHI) or M2-type (markers- CD14+, HLA-DR−, CD206+ and IL-10HI). (B) Polarized M2 macrophages (M-CSF, IL-4, and
IL-13) from HC volunteers (n = 7) and patients with CF (n = 7) are presented as percentage M1 or M2 of total macrophages measured by flow cytometry. (C) IL-10
cytokine levels from M1 and M2 polarized macrophages measured by ELISA. (D) Polarized M1 macrophages (GM-CSF, LPS, and IFNγ) from HC volunteers (n = 7)
and patients with CF (n = 7) are presented as percentage M1 or M2 of total macrophages measured by flow cytometry. (E) IL-6 cytokine levels from M1 and M2
polarized macrophages measured by ELISA. (F) mRNA relative expression of ER stress and UPR markers BiP, IRE1α, PERK, XBP1s, ERdj4, ATF4, CHOP, GADD34,
TNF, and IL-6 in M1 macrophages from HC volunteers (n = 9) and patients with CF (n = 9) at basal conditions and stimulated with LPS (100 ngml) for 4 h. (G) XBP1s
by RT-PCR in M1 macrophages from HC volunteers (n = 7) and CF patients (n = 9). (H,I) XBP1s levels in HC volunteers (n = 4) and CF (n = 5) M1 macrophages,
cells were lysed and immunoblotted for XBP1s and HPRT (H), XBP1s was normalized to HPRT and the ratios were compared to the levels of HC (I). (J) XBP1s levels
in HC volunteers (n = 4) and CF (n = 5) M2 macrophages, cells were lysed and immunoblotted for XBP1s and HPRT. All data is presented as mean ± SEM. Data in
panel F are represented by logarithmic scale base 10. All n values represent biological independent samples. Statistical comparisons were performed by
Mann-Whitney non-parametric test, *p < 0.05, **p < 0.01, ***p < 0.001 (B–E); unpaired independent student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001 (F,I).
FIGURE 4 | Glycolytic profile of CF monocytes and M1 macrophages. Real time ECAR and OCR of monocytes and M1 macrophages stimulated with glucose
(10mM), oligomycin (1µM), and 2-Deoxy-D-glucose (2-DG, 50mM). (A–D) Measurement of relative OCR (A) or ECAR (B) in monocytes from HC volunteers (n = 7)
and patients with CF (n = 7) at basal conditions and stimulated with LPS (10 ng/ml) for 4 h. Real time ECAR levels, glycolysis, glycolytic capacity and reserve (C,D).
Representative of 3 HC and 3 CF patients (C). (E–H) Measurement of relative OCR (E) or ECAR (F) in M1 macrophages from HC volunteers (n = 7) and patients with
CF (n = 7) at non-activated conditions and activated with LPS (50 ngml) and IFNγ (100 ng/ml). Real time ECAR, glycolysis, glycolytic capacity and reserve (G,H).
Representative of 3 HC and 3 CF patients (G). Glycolysis, glycolytic capacity, and reserve were calculated as described in the methods. The 7 CF patients and 7 HC
volunteers in (A–D), are independent from the other panels. All data is presented as mean ± SEM. All n values represent biological independent samples. Statistical
comparisons were performed by unpaired student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
(ESRRA), peroxisome proliferator activated receptor alpha
(PPARA), and uncoupling Protein 3 (UCP3), which are
involved in glycolysis and mitochondrial function. To our
surprise we detected a significant downregulation of HK2 and
PPARA in CF M1 macrophages, compared to the HC, with no
differences in PDK4, PFKB1, ESRRA, and UCP3 at the mRNA
level (Supplementary Figure 3). These results demonstrate
that monocytes and M1 macrophages from patients with CF
present an altered metabolic profile with increased ECAR and
OCR levels, which are qualitative indicators of mitochondrial
function and glycolytic rate, respectively. We also observed
a larger glycolytic capacity and reserve in these myeloid cells
from patients with CF. While the transcription levels of HK2
and PPARA were unexpectedly downregulated, this might
indicate that the high ECAR and OCR levels present in CF
M1 macrophages could be due to an increased activity of these
enzymes, rather than an increase in protein expression, further
work, which is outside the scope of the study, is required to test
this hypothesis.
We next investigated whether activation of the IRE1α-
XBP1 pathway, which was responsible for the high levels
of XBP1s, had an influence in the increased metabolic state
of CF M1 macrophages. As seen before the IRE1α-XBP1
pathway was significantly increased in CF M1 macrophages,
with increased levels of TNF and IL-6 (Figure 3F). By
inhibiting the IRE1α-XBP1 pathway, using specific IRE1α
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FIGURE 5 | The IRE1α-XBP1 pathway regulates metabolism in CF M1 macrophages. Real time ECAR and OCR of M1 macrophages stimulated with oligomycin
(1µM), FCCP (1µM), and rotenone/antimycin A (0.5µM). IRE1α inhibitors 4 µ8c (50µM) and MKC-3946 (10µM) were administrated 30min before M1 macrophages
activation. (A,B) Measurement of relative ECAR (A) or OCR (B) in M1 macrophages from HC volunteers (n = 9) and patients with CF (n = 9). (C,D) Real time OCR,
basal respiration, proton leak, maximal respiration, reserve capacity, and ATP production. All the values were calculated as described in the methods. Same CF
patients and HC volunteers were used in all panels and are the same subjects shown in Figure 6. All data is presented as mean ± SEM. Statistical comparisons were
performed by paired or unpaired student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
inhibitors, 4 µ8c and MKC-3946, before activation of M1
macrophages, we observed a reduction in the glycolytic rate
of 32.7 and 55.0%, respectively (Figure 5A). Similarly, the
increased mitochondrial rate of CF M1 macrophages was
reversed by the two inhibitors, reducing the OCR of CF
M1 macrophages by 34.5%, with 4 µ8c, and 45.5%, with
MKC-3946, comparable to the levels of HC M1 macrophages
(Figure 5B). We then measure different metabolic parameters
using modulators of mitochondrial respiration targeting key
components of the electron transport chain to measure cellular
basal respiration, proton leak, maximal respiration, reserve
respiratory capacity and ATP production. We found that CF M1
macrophages had a significant higher basal respiration and ATP
production compared to HC M1 macrophages (Figures 5C,D).
Remarkably, the two IRE1α inhibitors significantly reduced basal
respiration, maximal respiration, reserve respiratory capacity,
and ATP production in CF M1 macrophages (Figure 5D).
Surprisingly, we did not observe any differences in the
polarization ratio of M1 macrophages when the two IRE1α
inhibitors were administrated (Figure 6A). To confirm that
inhibition of the IRE1α-XBP1 pathway reduced the inflammatory
phenotype of M1 macrophages, we measured IL-6 and TNF
at the transcriptional and protein level. As expected, the two
inhibitors showed their potent suppressive effects on XBP1s
(Figure 6B); however, inhibition of the IRE1α-XBP1 pathway
only reduced the transcription levels of IL-6, but not TNF in
CF M1 macrophages (Figure 6B). Moreover, no differences were
detected in the levels of BiP or ERdj4 (Figure 6B). In accordance
with the IL-6 transcript levels, the two inhibitors significantly
reduced the amount of IL-6 produced by CF M1 macrophages
(Figure 6C). Even though TNF was not reduced at the mRNA
level, both inhibitors showed a strong TNF suppressive effect
at the cytokine level, with the 4 µ8c inhibitor showing a more
potent effect (Figure 6D). Together, these results demonstrate
that the IRE1α-XBP1 pathway is mainly responsible for the
hyper-metabolic state of CF M1 macrophages, which caused an
increased inflammatory response.
DISCUSSION
Macrophages are versatile cell types capable of controlling
the inflammatory response, as may be required by the
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FIGURE 6 | The IRE1α-XBP1 pathway regulates inflammatory cytokine secretion in CF M1 macrophages. IRE1 inhibitors 4 µ8c (50µM) and MKC-3946 (10µM) were
administrated 30min before M1 macrophages activation. (A) Polarized M1 macrophages from HC volunteers (n = 9) and patients with CF (n = 9) are presented as
percentage M1 of total macrophages measured by flow cytometry. (B) mRNA relative expression of ER stress and UPR markers BiP, XBP1s, ERdj4,TNF, and IL-6 in
M1 macrophages from HC volunteers (n = 6) and patients with CF (n = 6). (C,D) IL-6 and TNF cytokine levels from M1 macrophages measured by ELISA, HC
volunteers (n = 6) and patients with CF (n = 6). The same CF patients and HC volunteers were used in all panels. All data is presented as mean ± SEM. Data in panel
B are represented by logarithmic scale base 10. Statistical comparisons were performed by paired student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
prevailing physiological environment. M1 macrophages
promote an inflammatory response by secreting large amounts
of proinflammatory cytokines when polarized, while M2
macrophages are responsible for the resolution of inflammation
with large secretion of anti-inflammatory cytokines. CF has
been described as an autoinflammatory condition, due to the
lack of involvement of the adaptive immune system and an
overwhelming and chronic inflammatory response mainly
driven by the innate immune system (18). Autoinflammatory
conditions have been described as a self-directed inflammation
influenced by the local tissue environment leading to activation
of innate immune cells causing tissue damage and cellular death
(19). We demonstrated that patients with CF present unique
UPR activation, which is differentially upregulated in HBECs,
neutrophils, monocytes and M1 macrophages, while being
completely absent in adaptive immune cells. These findings
provide evidence to suggest that CF could be considered as an
autoinflammatory condition driven by the elevated ER stress
seen in innate immune cells with further repercussions in
inflammation. We have demonstrated that the IRE1α-XBP1
pathway induces a chronic degree of low-grade inflammation
in CF M1 macrophages, perhaps due to the accumulation of
misfolded CFTR in the ER, and this inflammatory response
can be exacerbated by further stimulation with bacterial
components, such as LPS (Figure 7). Similar findings were
found in autoinflammatory patients with Tumor Necrosis
Factor Receptor Associated Periodic Syndrome (TRAPS),
characterized by intracellular accumulation of misfolded
proteins, with enhanced IRE1α activity and inflammation
(20, 21). Furthermore, spontaneous lung and pancreatic
inflammation have been reported in several animal models
of CF, and in some models even in the absence of infection
(22–24). These observations support the idea that CF drives
an autoinflammatory phenotype, perhaps due to an increase
in ER stress, with a consequential formation of fibrotic tissue.
While the only differences we observed in CF PBMCs under
basal conditions were IRE1α, GADD34, and IL-6, contrary to the
differences found by Blohmke et al. (15), we observed changes
in a greater number of transcripts following stimulation with the
bacterial component, LPS, suggesting that bacterial infections
are the main environmental factors triggering ER stress and
inflammation in CF. The unexpected downregulation of IL-6,
in CF PMBCs, could be due to resolution of the inflammatory
response, as it was significantly higher after stimulation with
LPS (Figure 2A). Furthermore, there is a unique ER stress
signature in different subsets of immune cells, with consistent
upregulation of IRE1α. Despite the fact that neutrophils possess
a rudimentary ER, due to their biological functions and short
lifespan, we did observe a significant upregulation of BiP, IRE1α,
ATF4, and CHOP in these phagocytic cells. These findings
suggest an important role of these molecules in neutrophil
regulation, perhaps affecting their phagocytic or inflammatory
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FIGURE 7 | The IRE1α-XBP1 pathway of the UPR in CF. Activation of the IRE1α-XBP1 pathway in macrophages leads to splicing of XBP1 (XBP1s) which activates
transcription of genes involved in inflammation, protein folding, autophagy and metabolism. In CF macrophages malfunctioning and accumulation of the misfolded
CFTR induces a perpetual ER stress, leading to heightened levels in metabolic functions and chronic low-grade inflammation. TLR4 activation, through LPS, leads to a
hyper-inflammatory/metabolic response through XBP1s exacerbating the inflammatory response.
activity. Monocytes were the cells most affected by ER stress,
with consistent upregulation of IRE1α, ERdj4, PERK, ATF4,
GADD34, and TNF but without appreciable differences in
XBP1s expression. Interestingly, the significant upregulation of
XBP1s, detected in CF PBMCs after LPS stimulation, was not
observed in lymphocytes, neutrophils or monocytes, suggesting a
possible mechanistic interaction of immune cells to influence the
regulation of UPR genes. As monocytes are being differentiated
toward macrophages, their ER is expanded, and their cellular
size becomes enlarged, thereby providing these cells with a
greater capacity to promote inflammation and phagocytosis. As
previously reported (12), we observed a reduced of polarization
of M2 macrophages in patients with CF, which could be due
to increased levels of ER stress in these anti-inflammatory
cells. We did not detect any polarization abnormality in M1
macrophages; however, CF M1 macrophages displayed an
increased activity of the IRE1α-XBP1 pathway, with increased
BiP, XBP1s, ERdj4, TNF, and IL-6. Macrophages are phagocytic
cells directly involved in the clearance of pathogens. It has been
shown that macrophages with CF mutations present altered
phagocytic functions and bacterial killing (25–27). While a direct
connection between IRE1α activation and phagocytosis has not
been investigated, it is worth mentioning that XBP1s is directly
involved in the regulation of autophagy, by transcriptional
activation of BECLIN-1 (28). Furthermore, when XBP1s
is upregulated during bacterial challenge it will induce the
upregulation of components involved in autophagy; hence the
lysosomes will be utilized rapidly by the three main processes
involved in degradation of different components, namely
endocytosis, phagocytosis and autophagy, leading to deficient
bacterial killing and autophagy. It will be of great interest to
investigate whether the IRE1α-XBP1 pathway is involved in
phagocytosis not only in CF, but also in other disorders.
In line with previous investigations showing that the IRE1α-
XBP1 pathway is involved in maintaining the metabolic fitness
of immune cells (4), we found that this pathway regulates
metabolism in CF M1 macrophages. In our studies, we
observed an increased ECAR in CF monocytes, under basal
conditions, while both ECAR and OCR were largely increased
in CF monocytes after LPS stimulation, compared to HC
volunteers. This indicates that both the mitochondrial and
glycolytic function of CF monocytes were significantly increased
when challenged to bacterial components. Similarly, CF M1
macrophages displayed the same hyper-metabolic state before
and after polarization, suggesting that these abnormalities are
kept aftermacrophage polarization and in the absence of bacterial
infections. Furthermore, monocytes and M1 macrophages
presented an increased glycolytic capacity and reserve, which
could be due to the increased ER stress. These findings support
the idea that cells with CF mutations are adapted to chronic
ER stress, exacerbated by bacterial infections, improving their
ability to generate ATP. The increased levels in the glycolytic rate
and mitochondrial activity of CF M1 macrophages were reversed
by inhibition of the IRE1α-XBP1 pathway. This indicates that
this pathway is metabolically reprograming CF M1 macrophages
toward a hyper-metabolic state directly associated with the
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heightened inflammatory response. The two inhibitors, 4µ8c
and MKC-3946, showed a potent inhibitory effect in the
proinflammatory cytokines IL-6 and TNF. We did not detect
any changes in the polarization of M1 macrophages when the
inhibitors were administrated, perhaps due to the chronic ER
stress present in CF cells or, possibly, due to the surface markers
we used to characterize the macrophages. It is important to
mention that suppression of the RNase domain of IRE1α, with
the 4 µ8c and MKC-3946 inhibitors, not only decreases XBP1s,
but also several other important transcripts involved in cellular
homeostasis (29). Inhibition of the RNase domain of IRE1α
also interferes with the regulated IRE1-dependent decay (RIDD)
pathway (29); it has been shown that RIDD regulates around
120 transcripts in mammalian cells, with profound effects on
protein production and cellular fitness (30). For example, dermal
fibroblasts from patients with TRAPS fail to upregulate miR-
146a and miR-155, due to an increased activity in IRE1, which
can be reversed by inhibition of the RNase domain of IRE1α,
with 4 µ8c, thereby restoring the levels of miR-146a and miR-
155 (21). Another study showed that sustained activation of
RIDD influenced the cleavage of miR-17, miR-34a, miR-96, and
miR-125b, by repressing translation of Caspase-2 mRNA, which
controls the induction of apoptosis under chronic ER stress (31).
It is clear that RIDD is an important transcriptional regulator
involved in cellular homeostasis and fitness. It will be of great
interest to investigate whether the transcripts, targeted by RIDD
during ER stress in CF M1 macrophages, are linked to the
abnormal metabolic and inflammatory levels shown here.
In summary, activation of the IRE1α-XBP1 pathway in
CF M1 macrophages leads to a hyper-metabolic state, with
high levels of ECAR and OCR, associated with a heightened
inflammatory repose. The exaggerated inflammatory response
seen in patients with CF has been well established before, but
it has never been linked to an increased metabolic profile of
the classically activated macrophages. M1 macrophages from CF
patients undergo metabolic reprogramming, through the IRE1α-
XBP1 pathway, leading to high mitochondrial and glycolytic
activity, with associated increased levels of TNF and IL-6. These
findings help to explain why patients with CF suffer from chronic
and unresolved inflammation, not only present in the lungs but
also in joints, pancreas and gut (32–36). Malfunctioning of the
CFTR, along with accumulation of the misfolded channel, in the
case of 1F508 homozygous patients, induces a perpetual chronic
low-grade inflammation in CF macrophages, predisposing these
cells to a hyper-inflammatory and metabolic response, driven by
XBP1s, which is exacerbated by the activation of TLR4 (Figure 7)
and may be unresolved due to the lack of M2 macrophage
polarization. It is worthwhile mentioning that all CF patients
in our study were clinically stable, with a mean BMI of 23.1
and FEV1 of 45.9% (Table 1), indicating that our findings are
not due to the presence of clinical complications, but rather
to the CF mutations present in macrophages. Our findings are
in agreement with several investigations in the field of CF and
metabolism, which showed that the increased glycolytic rates
and mitochondrial activity were responsible for the abnormal
inflammatory responses. This connection is important in the
context of inflammation and metabolism, not only in CF,
but in other disorders also, showing that modulation of ER
stress, through inhibition of the IRE1α-XBP1 pathway, may
help to recover the metabolic fitness of immune cells in this
debilitating condition.
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript and/or the Supplementary Files.
ETHICS STATEMENT
All work involving human samples from patients with CF or
HC volunteers was approved by the Health Research Authority,
Research Ethics Committees reference 17/YH/0084.
AUTHOR CONTRIBUTIONS
SL-R, TS, FM, SS, DP, and MM: methodology. SL-R, TS,
and CW: validation, formal analysis, and data curation.
SL-R, TS, CW, JH, HJ-G, SS, DP, and MM: investigation
and writing–review and editing. SL-R, TS, SS, DP, and
MM: resources and funding acquisition. SL-R: writing–
original draft. SL-R and TS: visualization. SS, DP, and
MM: supervision.
FUNDING
This work was supported by a Cystic Fibrosis Trust Strategic
Research Center grant (SRC009) and by a charitable donation
from Gary Shuckford. SL-R was supported by CONACyT.
ACKNOWLEDGMENTS
The authors would like to thank all the patients and research
nurses, particularly Lindsey Gillgrass and Anne Wood, of
the Adult Cystic Fibrosis Unit at St. James’s Hospital, Leeds.
The authors would also like to thank Shelly Pathak for her
editorial advice.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.01789/full#supplementary-material
REFERENCES
1. Ribeiro CMP, Lubamba BA. Role of IRE1α/XBP-1 in Cystic Fibrosis Airway
Inflammation. Int J Mol Sci. (2017) 18:E118. doi: 10.3390/ijms18010118
2. Martinon F, Chen X, Lee AH, Glimcher LH. TLR activation of
the transcription factor XBP1 regulates innate immune responses
in macrophages. Nat Immunol. (2010) 11:411–8. doi: 10.1038/
ni.1857
Frontiers in Immunology | www.frontiersin.org 14 August 2019 | Volume 10 | Article 1789
Lara-Reyna et al. Metabolic Reprogramming of CF Macrophages
3. Piperi C, Adamopoulos C, Papavassiliou AG. XBP1: a pivotal transcriptional
regulator of glucose and lipid metabolism. Trends Endocrinol Metab. (2016)
27:119–22. doi: 10.1016/j.tem.2016.01.001
4. SongM, Sandoval TA, Chae CS, Chopra S, Tan C, RutkowskiMR, et al. IRE1α-
XBP1 controls T cell function in ovarian cancer by regulating mitochondrial
activity. Nature. (2018) 562:423–8. doi: 10.1038/s41586-018-0597-x
5. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H,
et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care
Med. (1995) 152(6 Pt 1):2111–8. doi: 10.1164/ajrccm.152.6.8520783
6. Zaman MM, Gelrud A, Junaidi O, Regan MM, Warny M, Shea JC,
et al. Interleukin 8 secretion from monocytes of subjects heterozygous
for the deltaF508 cystic fibrosis transmembrane conductance regulator
gene mutation is altered. Clin Diagn Lab Immunol. (2004) 11:819–24.
doi: 10.1128/CDLI.11.5.819-824.2004
7. Bonfield TL, Hodges CA, Cotton CU, Drumm ML. Absence of the cystic
fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows
resolution of inflammation and infection. J Leukoc Biol. (2012) 92:1111–22.
doi: 10.1189/jlb.0412188
8. Lubamba BA, Jones LC, O’Neal WK, Boucher RC, Ribeiro CM. X-box-
binding protein 1 and innate immune responses of human cystic fibrosis
alveolar macrophages. Am J Respir Crit Care Med. (2015) 192:1449–61.
doi: 10.1164/rccm.201504-0657OC
9. Tarique AA, Sly PD, Cardenas DG, Luo L, Stow JL, Bell SC, et al. Differential
expression of genes and receptors in monocytes from patients with cystic
fibrosis. J Cyst Fibros. (2018) 18:342–8. doi: 10.1016/j.jcf.2018.07.012
10. Sturges NC, Wikstrom ME, Winfield KR, Gard SE, Brennan S, Sly PD,
et al. Monocytes from children with clinically stable cystic fibrosis show
enhanced expression of Toll-like receptor 4. Pediatr Pulmonol. (2010) 45:883–
9. doi: 10.1002/ppul.21230
11. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al.
Macrophage activation and polarization: nomenclature and experimental
guidelines. Immunity. (2014) 41:14–20. doi: 10.1016/j.immuni.2014.06.008
12. Tarique AA, Sly PD, Holt PG, Bosco A, Ware RS, Logan J, et al. CFTR-
dependent defect in alternatively-activated macrophages in cystic fibrosis. J
Cyst Fibros. (2017) 16:475–82. doi: 10.1016/j.jcf.2017.03.011
13. Zhang S, Shrestha CL, Kopp BT. Cystic fibrosis transmembrane
conductance regulator (CFTR) modulators have differential effects
on cystic fibrosis macrophage function. Sci Rep. (2018) 8:17066.
doi: 10.1038/s41598-018-35151-7
14. Shan B, Wang X, Wu Y, Xu C, Xia Z, Dai J, et al. The metabolic ER stress
sensor IRE1α suppresses alternative activation of macrophages and impairs
energy expenditure in obesity. Nat Immunol. (2017) 18:519–29. doi: 10.1038/
ni.3709
15. Blohmke CJ, Mayer ML, Tang AC, Hirschfeld AF, Fjell CD, Sze MA,
et al. Atypical activation of the unfolded protein response in cystic fibrosis
airway cells contributes to p38 MAPK-mediated innate immune responses. J
Immunol. (2012) 189:5467–75. doi: 10.4049/jimmunol.1103661
16. Ron D, Walter P. Signal integration in the endoplasmic reticulum
unfolded protein response. Nat Rev Mol Cell Biol. (2007) 8:519–29.
doi: 10.1038/nrm2199
17. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al.
Succinate dehydrogenase supports metabolic repurposing of mitochondria
to drive inflammatory macrophages. Cell. (2016) 167:457–70.e13.
doi: 10.1016/j.cell.2016.08.064
18. Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field
of innate immune-mediated disease and autoinflammation. J Pathol. (2017)
241:123–39. doi: 10.1002/path.4812
19. McGonagle D, McDermott MF. A proposed classification
of the immunological diseases. PLoS Med. (2006) 3:1242–8.
doi: 10.1371/journal.pmed.0030297
20. Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J, et al.
Involvement of X-box binding protein 1 and reactive oxygen species
pathways in the pathogenesis of tumour necrosis factor receptor-
associated periodic syndrome. Ann Rheum Dis. (2012) 71:2035–43.
doi: 10.1136/annrheumdis-2011-201197
21. Harrison SR, Scambler T, Oubussad L, Wong C, Wittmann M,
McDermott MF, et al. Inositol-requiring enzyme 1-mediated
downregulation of MicroRNA (miR)-146a and miR-155 in primary
dermal fibroblasts across three TNFRSF1A mutations results in
hyperresponsiveness to lipopolysaccharide. Front Immunol. (2018) 9:173.
doi: 10.3389/fimmu.2018.00173
22. Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P, et al.
Azithromycin reduces spontaneous and induced inflammation in DeltaF508
cystic fibrosis mice. Respir Res. (2006) 7:134. doi: 10.1186/1465-9921-7-134
23. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP,
Davis GJ, et al. Cystic fibrosis pigs develop lung disease and exhibit
defective bacterial eradication at birth. Sci Transl Med. (2010) 2:29ra31.
doi: 10.1126/scitranslmed.3000928
24. Keiser NW, Engelhardt JF. New animal models of cystic fibrosis:
what are they teaching us? Curr Opin Pulm Med. (2011) 17:478–83.
doi: 10.1097/MCP.0b013e32834b14c9
25. Simonin-Le Jeune K, Le Jeune A, Jouneau S, Belleguic C, Roux PF, Jaguin M,
et al. Impaired functions of macrophage from cystic fibrosis patients: CD11b,
TLR-5 decrease and sCD14, inflammatory cytokines increase. PLoS ONE.
(2013) 8:e75667. doi: 10.1371/journal.pone.0075667
26. Porto PD, Cifani N, Guarnieri S, Di Domenico EG, Mariggiò MA, Spadaro
F, et al. Dysfunctional CFTR alters the bactericidal activity of human
macrophages against Pseudomonas aeruginosa. PLoS ONE. (2011) 6:e19970.
doi: 10.1371/journal.pone.0019970
27. Leveque M, Le Trionnaire S, Del Porto P, Martin-Chouly C. The impact of
impaired macrophage functions in cystic fibrosis disease progression. J Cyst
Fibros. (2017) 16:443–53. doi: 10.1016/j.jcf.2016.10.011
28. Margariti A, Li H, Chen T, Martin D, Vizcay-Barrena G, Alam S, et al.
XBP1 mRNA splicing triggers an autophagic response in endothelial cells
through BECLIN-1 transcriptional activation. J Biol Chem. (2013) 288:859–72.
doi: 10.1074/jbc.M112.412783
29. Coelho DS, Domingos PM. Physiological roles of regulated Ire1 dependent
decay. Front Genet. (2014) 5:76. doi: 10.3389/fgene.2014.00076
30. Hollien J, Lin JH, Li H, Stevens N, Walter P, Weissman JS. Regulated Ire1-
dependent decay of messenger RNAs in mammalian cells. J Cell Biol. (2009)
186:323–31. doi: 10.1083/jcb.200903014
31. Upton JP, Wang L, Han D, Wang ES, Huskey NE, Lim L, et al. IRE1α cleaves
select microRNAs during ER stress to derepress translation of proapoptotic
Caspase-2. Science. (2012) 338:818–22. doi: 10.1126/science.1226191
32. Clarke EA, Watson P, Freeston JE, Peckham DG, Jones AM, Horsley A.
Assessing arthritis in the context of cystic fibrosis. Pediatr Pulmonol. (2019)
54:770–7. doi: 10.1002/ppul.24290
33. Gibson-Corley KN, Meyerholz DK, Engelhardt JF. Pancreatic
pathophysiology in cystic fibrosis. J Pathol. (2016) 238:311–20.
doi: 10.1002/path.4634
34. Witt H. Chronic pancreatitis and cystic fibrosis.Gut. (2003) 52 (Suppl 2):ii31–
41. doi: 10.1136/gut.52.suppl_2.ii31
35. Munck A. Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell
Biol. (2014) 52:180–3. doi: 10.1016/j.biocel.2014.02.005
36. Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, et al.
Impact of CFTR modulation with ivacaftor on gut microbiota and
intestinal inflammation. Sci Rep. (2018) 8:17834. doi: 10.1038/s41598-018-
36364-6
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Lara-Reyna, Scambler, Holbrook, Wong, Jarosz-Griffiths,
Martinon, Savic, Peckham andMcDermott. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 15 August 2019 | Volume 10 | Article 1789
